Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging

Table 4 Performance of the mean reduction rate of T1 relaxation time and hepatocyte fraction for the prediction of METAVIR fibrosis stages according to cut-off values

Parameters	≥ F1	≥ F2	≥ F3	= F4
Cut-off
HeF (%)	82.93	79.24	74.37	74.37
RE	0.75	0.73	0.72	0.72
AUC
HeF (%)	0.837 (0.733-0.913)	0.890 (0.795-0.951)	0.957 (0.881-0.990)	0.957 (0.882-0.991)
RE	0.678 (0.559-0.783)	0.723 (0.606-0.821)	0.921 (0.834-0.971)	0.962 (0.889-0.993)
Sensitivity, %
HeF(%)	72.0 (57.5-83.8)	77.4 (58.9-90.4)	94.4 (72.7-99.9)	100.0 (73.5-100.0)
RE	44.0 (30.0-58.7)	58.1 (39.1-75.5)	88.9 (65.3-98.6)	100.0 (73.5-100.0)
Specificity, %
HeF (%)	82.6 (61.2-95.0)	92.9 (80.5-98.5)	92.7 (82.4-98.0)	85.3 (73.8-93.0)
RE	100.0 (85.2-100.0)	92.9 (80.5-98.5)	92.7 (82.4-98.0)	86.9 (75.8-94.2)
PPV, %
HeF (%)	90.0 (76.3-97.2)	88.9 (70.8-97.6)	81.0 (58.1-94.6)	57.1 (34.0-78.2)
RE	100.0 (84.6-100.0)	85.7 (63.7-97.0)	80.0 (56.3-94.3)	60.0 (36.1-80.9)
NPV, %
HeF (%)	57.6 (39.2-74.5)	84.8 (71.1-93.7)	98.1 (89.7-100.0)	100.0 (93.2-100.0)
RE	45.1 (31.1-59.7)	75.0 (61.1-86.0)	96.2 (87.0-99.5)	100.0 (93.3-100.0)
PLR
HeF (%)	4.14 (1.7-10.3)	10.84 (3.6-32.8)	12.99 (5.0-33.6)	6.78 (3.7-12.4)
RE	_	8.13 (2.6-25.2)	12.22 (4.7-31.8)	7.62 (4.0-14.5)
NLR
HeF (%)	0.34 (0.2-0.5)	0.24 (0.1-0.5)	0.060 (0.009-0.4)	_
RE	0.56 (0.4-0.7)	0.45 (0.3-0.7)	0.12 (0.03-0.4)	_

AUC: Area under the curve; HeF: Hepatocyte fraction; NLR: Negative likelihood ratio; NPV: Negative predictive value; PLR: Positive likelihood ratio; PPV: Positive predictive value; RE: Reduction rate of T1 relaxation time.